(Q37886792)

24 August 2017

1 reference

title

Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

24 August 2017

0 references

1 reference

1 reference

W Nseir

1

1 reference

24 August 2017

A Shalata

series ordinal

2

1 reference

24 August 2017

A Marmor

series ordinal

3

1 reference

24 August 2017

N Assy

series ordinal

4

1 reference

24 August 2017

publication date

8 June 2011

1 reference

Digestive Diseases and Sciences

24 August 2017

published in

1 reference

24 August 2017

volume

56

1 reference

24 August 2017

issue

12

1 reference

24 August 2017

page(s)

3439-3449

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-011-1767-y

24 August 2017

exact match

0 references

cites work

Nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Non-alcoholic fatty liver disease and increased risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Nonalcoholic fatty liver disease: an agenda for clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

The natural history of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Metabolic syndrome and incident diabetes: current state of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Sonographic fatty liver, overweight and ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Presence of coronary plaques in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Nonalcoholic fatty liver disease and carotid atherosclerosis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Gamma Glutamyl Transferase and Metabolic Syndrome, Cardiovascular Disease, and Mortality Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Obesity is the only independent factor associated with ultrasound-diagnosed non-alcoholic fatty liver disease: a cross-sectional case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Serum folate and homocysteine levels in obese females with non-alcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Epidemiology of nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Gender, fatty liver and GGT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Physical activity and the incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Nonalcoholic fatty liver disease and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Fatty infiltration of liver in hyperlipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26 year observation period: the Manitoba Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Selection and outcome of living donors for adult to adult right lobe transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Liver histology in a 'normal' population--examinations of 503 consecutive fatal traffic casualties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Nonalcoholic steatohepatitis: a study of 49 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Mitochondrial adaptations to obesity-related oxidant stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Oxidative stress, antioxidants, and endothelial function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Obstructive sleep apnea syndrome and fatty liver: association or causal link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Insulin resistance: a metabolic pathway to chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Causes and metabolic consequences of Fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Inflammation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Mechanisms linking obesity with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

21 January 2018

From fat to inflammation

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Inflammation in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Implications of myocardial matrix remodeling by adipokines in obesity-related heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

New insight into the pathophysiology of lipid abnormalities in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism: a kinetic study in control subjects and patients with type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Overproduction of large VLDL particles is driven by increased liver fat content in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Postprandial hyperlipidemia and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

A macrophage receptor for apolipoprotein B48: cloning, expression, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

The interactions between inflammation and coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Olive oil consumption and non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Soft drinks consumption and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1767-Y

Statins and hepatic steatosis: perspectives from the Dallas Heart Study

21 January 2018

1 reference

12 December 2020

Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study

1 reference

12 December 2020

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

12 December 2020

Regular physical activity and coronary risk factors in Japanese men

1 reference

12 December 2020

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

1 reference

12 December 2020

Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease

1 reference

12 December 2020

High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis.

1 reference

12 December 2020

Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease

1 reference

12 December 2020

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

1 reference

12 December 2020

Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery

1 reference

12 December 2020

Dipeptidyl peptidase IV (DDP IV) in NASH patients.

1 reference

12 December 2020

Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men. A general population study

1 reference

12 December 2020

Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study

1 reference

12 December 2020

Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes.

1 reference

12 December 2020

Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study

1 reference

12 December 2020

Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients.

1 reference

12 December 2020

The impact of postprandial lipemia in accelerating atherothrombosis

1 reference

12 December 2020

Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation

1 reference

12 December 2020

Diabetic dyslipidaemia

1 reference

12 December 2020

A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients

1 reference

12 December 2020

Overexpression of hepatic plasminogen activator inhibitor type 1 mRNA in rabbits with fatty liver

1 reference

12 December 2020

Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease

1 reference

12 December 2020

Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study

1 reference

12 December 2020

Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease

1 reference

12 December 2020

Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease

1 reference

12 December 2020

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

1 reference

12 December 2020

Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome status: one-year results of the PREDIMED randomized trial.

1 reference

12 December 2020

Nonalcoholic fatty liver disease in overweight children and adolescents

1 reference

12 December 2020

10.1007/S10620-011-1767-Y

Identifiers

DOI

1 reference

24 August 2017

1 reference